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Purpose: To identify genetic variants associated with complement activation, which may help to select
age-related macular degeneration (AMD) patients for complement-inhibiting therapies.
Design: Genome-wide association study (GWAS) followed by replication and meta-analysis.
Participants: AMD patients and controls (n ¼ 2245).
Methods: A GWAS on serum C3d-to-C3 ratio was performed in 1548 AMD patients and controls. For
replication and meta-analysis, 697 additional individuals were genotyped. A model for complement activation
including genetic and non-genetic factors was built, and the variance explained was estimated. Haplotype
analysis was performed for 8 SNPs across the CFH/CFHR locus. Association with AMD was performed for the
variants and haplotypes found to influence complement activation.
Main Outcome Measures: Normalized C3d/C3 ratio as a measure of systemic complement activation.
Results: Complement activation was associated independently with rs3753396 located in CFH (Pdiscovery ¼
1.09  1015; Pmeta ¼ 3.66  1021; b ¼ 0.141; standard error [SE] ¼ 0.015) and rs6685931 located in CFHR4
(Pdiscovery ¼ 8.18  107; Pmeta ¼ 6.32  108; b ¼ 0.054; SE ¼ 0.010). A model including age, AMD disease
status, body mass index, triglycerides, rs3753396, rs6685931, and previously identified SNPs explained 18.7% of
the variability in complement activation. Haplotype analysis revealed 3 haplotypes (H1e2 and H6 containing
rs6685931 and H3 containing rs3753396) associated with complement activation. Haplotypes H3 and H6
conferred stronger effects on complement activation compared with the single variants (P ¼ 2.53  1014; b ¼
0.183; SE ¼ 0.024; and P ¼ 4.28  104; b ¼ 0.144; SE ¼ 0.041; respectively). Association analyses with AMD
revealed that SNP rs6685931 and haplotype H1e2 containing rs6685931 were associated with a risk for AMD
development, whereas SNP rs3753396 and haplotypes H3 and H6 were not.
Conclusions: The SNP rs3753396 in CFH and SNP rs6685931 in CFHR4 are associated with systemic
complement activation levels. The SNP rs6685931 in CFHR4 and its linked haplotype H1e2 also conferred a risk
for AMD development, and therefore could be used to identify AMD patients who would benefit most
from complement-inhibiting therapies. Ophthalmology 2018;125:1064-1074 ª 2018 by the American Academy of
Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
See Editorial on page 962.
Supplemental material available at www.aaojournal.org.
The complement system is an integral part of our innate
immunity. Its best known physiologic functions are host
defense against foreign intruders and homeostasis mainte-
nance.1 It consists of more than 30 plasma proteins and
cellular components that interact in proteolytic cascades
for an efficient and rapid activation leading to
inflammation, opsonization, and targeted cytolysis.2 The
complement system can be activated by 3 different
pathways: the classical pathway, the lectin pathway, and
the alternative pathway (AP). The classical pathway is
activated by antibodyeantigen complexes and the lectin
pathway is activated by lectin or ficolin binding to
carbohydrates, both on the surfaces of pathogens. In
contrast, the AP is activated constitutively at a low level
in a process known as tick-over.3
All 3 pathways lead to the formation of complement
component 3 (C3) convertases that catalyze a proteolytic
cleavage of complement C3 into the potent anaphylatoxin
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C3a, and C3b, an opsonization molecule that can be further
cleaved into C3d. Complement component 3b also can bind
the cleaved form of factor B (Bb) to form the AP C3 con-
vertase (C3bBb) that will cleave more C3, initiating an
amplification loop. Downstream in the cascade, complement
component 5 convertases are formed, initiating the terminal
pathway with the subsequent formation of additional acti-
vation products as well as the membrane-attack complex
that is responsible for cytolysis.4 The complement system
can be amplified rapidly, and therefore several inhibitory
proteins such as complement factor H (FH) and
complement factor I are in place regulating complement
activity.4
Deregulation and deficiencies of the complement system
have been reported to be associated with numerous
inflammatory, autoimmune, neurodegenerative, and infec-
tious disorders.5 A prime example of a multifactorial disease
associated with a deregulation of the complement system is
age-related macular degeneration (AMD). Age-related
macular degeneration is characterized by a progressive
degeneration of the central retina and is responsible for most
cases of vision loss in the elderly with a pooled prevalence
of 8.9%.6,7 Age-related macular degeneration constitutes a
major health problem as by 2020, the number of people
affected by a form of this disease is projected to be 196
million, rising to 288 million by 2040.8 Several lines of
evidence point toward an overactivation of the
complement system in AMD, mainly through a
dysregulation of the AP. Multiple genetic variants in or
near complement genes (CFH, C3, CFI, C2/CFB locus,
and C9) have been associated strongly with AMD.9,10
Moreover, complement components have been described
in drusen, the hallmark of the disease,11e14 and complement
activation fragments in plasma or serum such as Ba, C3a,
C3d, and component C5a have been found to be elevated
significantly in AMD patients compared with controls.15e21
Currently, there is no treatment available for most forms of
AMD, nor is there an effective means to halt AMD pro-
gression. Therefore, therapies for AMD, as well as for other
diseases involving complement deregulation, are being
developed aiming to inhibit or lower complement
activation.22e24
Systemic complement activation levels demonstrate
considerable variation among individuals.16e20 As a
consequence, patients who have higher levels of comple-
ment activation may benefit more than others from the up-
coming therapies. A better understanding of the factors that
influence complement activation would facilitate the selec-
tion of the most suitable patients for complement-inhibiting
therapies. Genetic markers are robust biomarkers that could
be included in prediction models for complement activation.
Several studies have previously evaluated the effect of
genetic variation on complement activity; however, these
studies were restricted to a limited number of single
nucleotide polymorphisms (SNPs).16e19,21,25
The aim of this study was to perform the first genome-
wide association study (GWAS) on systemic complement
activation levels. Identification of genetic variants explain-
ing complement activation levels will contribute to a better
understanding of the molecular mechanisms of complement-
related diseases, will pinpoint potential drug targets, and
will facilitate the selection of patients for complement-
inhibiting therapies.
Methods
Study Population
This study included 2245 participants from the European Genetic
Database (www.eugenda.org). The European Genetic Database is a
multicenter database for the clinical and molecular analysis of
AMD collected at the Radboud University medical center,
Nijmegen, The Netherlands, and at the University Hospital of
Cologne, Cologne, Germany. The study participants were sepa-
rated into 2 cohorts: a discovery cohort comprising 1548 in-
dividuals and a replication cohort of 697 individuals.
The study was performed in accordance with the tenets of the
Declaration of Helsinki (seventh revision) and the Medical
Research Involving Human Subjects Act. Approval of the local
ethics committee of both University hospitals was obtained, and
written informed consent was acquired from all participants. All
the individuals included in the study agreed to the performed serum
measurements and genotyping. All participants were of European
descent and older than 50 years. Age-related macular degeneration
and control status were assigned by multimodal image grading
according to the standard protocol of the Cologne Image Reading
Center by certified graders. Age, sex, height, and weight mea-
surements were obtained by standardized interviewer-assisted
questionnaires.
Serum Complement and Lipid Measurements
Serum was obtained by a standard coagulation and centrifugation
protocol, and within 1 hour after collection, the samples were
stored at 80C. Triglycerides and high-density lipoprotein
cholesterol were measured using standard procedures by a clinical
chemistry laboratory (Architect Analyzer; Abbott Diagnostics,
Hoofddorp, The Netherlands). Complement component 3 was
assessed by radial immunodiffusion (or Mancini method) using
monospecific polyclonal rabbit antisera, and C3d was measured by
rocket electrophoresis, as previously described.21 Complement
component 3d is a fragment of C3 generated upon activation of
the system, and therefore a direct measurement of complement
turnover.4 Moreover, C3d has the longest half-life of all C3 split
products.26 The C3d-to-C3 ratio is a sensitive way of assessing the
activation of the complement system independently of the baseline
individual C3 concentration.27e29 The C3d-to-C3 ratio has been
described previously to be a robust biomarker for complement
activation in AMD studies.19 The different measurements were
performed for all samples in a single assay.
Genotyping
Genomic DNA was extracted from peripheral blood samples using
standard procedures. The discovery cohort was genotyped with a
custom-designed HumanCoreExome array by Illumina (Illumina
Inc., San Diego, CA) within the International AMD Genetics
Consortium. All the details regarding the design of the array,
annotation, imputation, and quality control of the genotypic data
have been described previously.9
Imputed lead variants in GWAS peaks that reached signifi-
cance, rs6685931 and rs3130572, were confirmed by polymerase
chain reaction and Sanger sequencing. The SNP rs6685931 was
evaluated in 12 individuals representing the 3 genotypes, and a
100% of concordance with the imputed genotypes was achieved.
The SNP rs3130572 (chromosome 6) was located in a highly
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repetitive region and specific primers could not be designed;
therefore, this SNP was excluded from further analysis. In the
replication cohort, CFH rs3753396 and CFHR4 rs6685931 were
genotyped using competitive allele-specific polymerase chain
reaction assays according to the manufacturer instructions (KASP
Genotyping Chemistry; LGC, Hoddesdon, UK).
Statistical Analysis
Natural log transformation was applied to normalize the skewed
distribution of C3d/C3 measurements. A general linear model for
ln(C3d/C3) including as independent variables the environmental
factors collected was used to determine potential confounders. The
R2 and adjusted R2 statistics were estimated for the model. Addi-
tionally, the R2 statistic was estimated for each of the independent
factors individually, performing separate models. Analyses were
carried out using SPSS software version 20.0 (IBM Software and
Systems, Armonk, NY).
A power calculation for the GWAS was performed using the
Genetic power calculator.30 Association tests in the GWAS and
replication analyses were performed by means of a linear Wald
test from EPACTS software (http://genome.sph.umich.edu/wiki/
EPACTS) using allele dosages. Linear regression models
adjusted for age, sex, body mass index (BMI), triglycerides,
clinic site, and the first 2 ancestry principal components were
used. Manhattan and Q-Q plots were generated using the
‘qqman’ R package (version 0.1.2; R Foundation for Statistical
Computing, Vienna, Austria). The regional plots for chromosome
1 were generated using LocusZoom.31 Meta-analysis of fixed ef-
fects based on effect size estimates and standard errors was per-
formed using METAL software (version 2-11-03-25).32
Evaluation of an interaction between the identified SNPs and
clinic or AMD status was performed including an interaction
parameter on the general linear model and assessing nominal sig-
nificance. Comparisons of systemic complement activation levels
between the genotype groups were performed using a general
linear model adjusted for age, BMI, triglycerides, and clinic sites
including both the discovery and the replication cohorts. SPSS
software version 20.0 (IBM Software and Systems, Armonk, NY)
was used for these analyses.
To estimate how much of the variation in systemic complement
activation could be explained by the identified factors, general
linear models for systemic complement activation were performed
using SPSS software version 20.0. Only the 1548 individuals from
the discovery cohort were included to accommodate the CFH
rs800292 and C2 rs9332739 SNPs, which were not analyzed in the
replication cohort. The adjusted R2 statistic was estimated for the
models.
Haplotype analysis was carried out for the 1548 patients geno-
typed with exome-arrays using the haplo.glm function of the R
library ‘haplo.stats’ (version 1.7.7). Analysis was performed based
on a general linear model adjusted for age, sex, BMI, triglycerides,
clinic site, and the first 2 ancestry principal components.
Single-variant and haplotype association analyses with AMD
were performed for the 1548 individuals of the discovery cohort.
Single-variant analyses were performed using a Firth bias-
corrected likelihood-ratio test with EPACTS software. Haplotype
analyses were based on chi-squared tests including haplotypes with
a predicted probability of 0.75 or more using SPSS software
version 20.0.
Risk scores for AMD-associated variants were calculated as a
sum of the number of AMD risk-increasing alleles. Two risk scores
were calculated: the first risk score included the 52 AMD-
associated variants described in Fritsche et al,9 and the second
risk score included the 19 variants located in or near complement
genes of these 52. The variants included in the complement risk
score were: rs10922109, rs570618, rs121913059, rs148553336,
rs187328863, rs61818925, rs35292876, and rs191281603 from
the CFH locus; rs10033900 and rs141853578 from the CFI
locus; rs62358361 from the C9 locus; rs116503776,
rs144629244, rs114254831, and rs181705462 from the C2/CFB/
SKIV2L locus; rs11080055 from the TMEM97/VTN locus; and
rs2230199, rs147859257, and rs12019136 from the C3 locus.
The risk scores were included in linear models for ln(C3d/C3)
that included age, BMI, triglycerides, and clinic site as
covariates, and the effect of the risk score was estimated. The
1548 individuals from the discovery phase, genotyped with the
HumanCoreExome array, were included in these analyses.
Figures including graphs were generated using Graphpad Prism
version 5.03 (GraphPad Software, La Jolla, CA).
Results
Characteristics of the Study Cohorts
We evaluated the association of genetic variants with systemic
complement activation levels through a GWAS in a discovery
cohort of 1548 individuals, followed by replication in an inde-
pendent cohort of 697 individuals. For both cohorts, demographics
and information about AMD disease status, BMI, triglycerides, and
high-density lipoprotein cholesterol was collected (Table 1).
Higher complement activation levels were associated indepen-
dently with older age, AMD disease status, lower BMI, and lower
triglyceride levels as previously described.21,33 Differences also
were observed between the sample collection clinics (Table S2,
available at www.aaojournal.org). Therefore, these factors were
included as covariates in all consecutive analyses.
Genome-Wide Association Study Identifies 2
Independent Signals at the CFH/CFHR Locus to
Be Associated with Systemic Complement
Activation
We carried out a GWAS of normalized C3d/C3 levels as a measure
of systemic complement activation. After quality control, a total of
1548 individuals and 9 972 920 variants were included in the
analysis. The study had more than 80% of power to detect common
variants (minor allele frequency 5%), explaining 2.6% or more
of variance in complement activation levels.
A total of 280 variants reached genome-wide significance
(Manhattan plot, Fig 1A; QQplot, Fig S2, available at
www.aaojournal.org; lGC ¼ 0.999). All variants, except for one,
were located on chromosome 1 at the CFH/CFHR locus
(chromosome 1, 196.643.724e197.061.086). The only variant
outside of this locus was located on chromosome 6 near the
PSORS1C1 gene, but could not be verified by Sanger
sequencing. The SNP rs3753396 (c.2016A/G, p.Gln672Gln)
located in exon 14 of the complement factor H (CFH) gene
showed the strongest association with complement activation
levels (P ¼ 1.09  1015; b ¼ 0.145; standard error [SE],
0.018; Table 3; locus zoom depicted in Fig 1B).
Conditional analysis on the lead SNP revealed a second inde-
pendent signal with a P value close to genome-wide significance
for which the strongest associated variant was rs6685931. This
SNP was also located at the CFH/CFHR locus, specifically in
intron 1 (c.59e4315T/C) of the complement factor H related 4
(CFHR4) gene (P ¼ 8.18  107; b ¼ 0.068; SE, 0.014; Table 3;
locus zoom depicted in Fig 1C).
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Figure 1. Graphs showing that the genome-wide association study identified 2 independent signals at the CFH/CFHR locus associated with systemic
complement activation levels. A, Manhattan plot illustrating the P values of each individual single nucleotide polymorphism (SNP) tested for association
with systemic complement activation. The red horizontal line indicates the threshold considered for genome-wide significance (P ¼ 5  108). B, Locus
zoom plot showing a detailed view of the chromosome 1 signal. The lead SNP rs3753396 is located in the CFH gene. The SNPs are colored based on their
linkage disequilibrium estimate (r2) to the lead SNP. C, Locus zoom plot showing a detailed view of the signal on chromosome 1 (chr1) after conditioning
the association analysis for rs3753396. Here, the lead SNP rs6685931 is located in the CFHR4 gene. The SNPs are colored based on their linkage
disequilibrium estimate (r2) to the lead SNP.
Table 1. Demographics and Other Characteristics of the Discovery and Replication Cohorts
Discovery Cohort (n [ 1548) Replication Cohort (n [ 697)
Complement activation ln(c3d/c3), mean (SD) 1.459 (0.407) 1.464 (0.398)
Age (yrs), mean (SD) 73.2 (7.8) 73.3 (7.7)
Female sex (%) 60 58.8
AMD disease status, control (%) 53.7 37.4
BMI (kg/m2), median (quartiles) 25 (23e28) 25 (23e28)
Triglycerides (mmol/l), median (quartiles) 1.620 (1.170e2.220) 1.620 (1.165e2.210)
HDL cholesterol (mmol/l), mean (SD) 1.489 (0.377) 1.478 (0.403)
Clinic site - Radboud university medical center (%) 53.5 63
AMD ¼ age-related macular degeneration; BMI ¼ body mass index; HDL ¼ high-density lipoprotein; SD ¼ standard deviation.
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Variants shown to be associated with complement activation
fragments in previous studies were extracted from the GWAS re-
sults.17,18 The SNP rs800292 in CFH and the 2 SNPs in linkage
disequilibrium rs4151667 in CFB and rs9332739 in C2 were
associated nominally with systemic complement activation levels
in the current study, showing the same direction of the effect. The
SNP rs2230199 in C3 and the SNP rs10490924 in ARMS2 could
not be replicated (Table S4, available at www.aaojournal.org).
Replication in an Independent Cohort Confirms
the Effect of rs3753396 in CFH and rs6685931 in
CFHR4 on Systemic Complement Activation
Replication analysis of rs3753396 in CFH and rs6685931 in
CFHR4 in an independent cohort of 697 study participants
confirmed both variants to be associated significantly with systemic
complement activation levels (rs3753396: P ¼ 1.39  106;
b ¼ 0.131; SE, 0.027; and rs6685931: P ¼ 8.62  103;
b ¼ 0.038; SE, 0.014; Table 3). Subsequent meta-analysis showed
associations for both rs3753396 (P ¼ 3.66  1021; b ¼ 0.141;
SE, 0.015) and rs6685931 (P ¼ 6.32  108; b ¼ 0.054; SE,
0.010), confirming that 2 independent signals at the CFH/CFHR
locus are associated with higher complement activation levels
(Table 3). Sensitivity analyses adjusting for AMD disease status
showed comparable results (Table S5, available at
www.aaojournal.org), and neither an interaction between clinic
site and the identified SNPs (Prs3753396  clinic ¼ 0.436;
Prs6685931  clinic ¼ 0.676), nor an interaction between AMD
status and the identified SNPs (Prs3753396  AMD status ¼ 0.557;
Prs6685931  AMD status ¼ 0.658) was detected.
Next, mean complement activation levels in the genotype groups
of rs373396 and rs6685931 were analyzed. For rs3753396 in CFH,
the heterozygous AG genotype group showed higher complement
activation levels compared with the reference AA genotype group
(P¼ 6.23 1018; b¼ 0.152; SE, 0.018), and for the homozygous
GG group, these levels were even higher (P ¼ 2.39  107;
b¼ 0.267; SE, 0.052; Fig 3A). In the case of rs6685931 inCFHR4, a
similar effect was observed: the heterozygous TC genotype group
had higher complement activation levels than the reference TT
genotype (P ¼ 103; b ¼ 0.063; SE, 0.019) and for the
homozygous CC group, the levels were even higher (P ¼ 3.62 
107; b ¼ 0.118; SE, 0.023; Fig 3B). Analysis of the cumulative
effect of both SNPs showed that the main effect on systemic
complement activation levels is driven by rs3753396 in CFH, and
rs6685931 in CFHR4 introduces additional variation to the
rs3753396 genotypes (Fig 3C).
A Model of Genetic and Nongenetic Variables
Explains 18.7% of the Variability in Complement
Activation
General linear models were built to determine how much of the
variation could be explained by factors found to be associated with
systemic complement activation. A model including only non-
genetic factors (age, AMD disease status, BMI, and triglycerides)
explained 12.6% of the variability in systemic complement acti-
vation. With the addition of SNP rs3753396 to the model, 16.3% of
the variability could be explained, and by including SNP
rs6685931, a total of 17.3% was explained. We additionally
incorporated SNPs associated with complement activation frag-
ments in a previous study that replicated in our GWAS: rs800292
in CFH and rs9332739 in C2.18 Only rs9332739 remained
associated independently with systemic complement activation
levels, and the variance explained by the model rose to 18.7%
(adjusted R2; Table 6).
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Haplotypes across the CFH/CFHR Locus Show
Stronger Effects on Systemic Complement
Activation Levels Compared with Individual
Variants
To assess whether more variants at the CFH/CFHR locus influence
systemic complement activation and to determine the cumulative
effect of several variants on the same haplotype, we evaluated the
effect of distinct haplotypes across the CFH/CFHR locus on sys-
temic complement activation. Haplotypes previously described for
AMD already included rs3753396, the lead variant associated in
the GWAS,34 and were expanded by adding rs668593, the second
independent signal. In total, 7 SNPs across the CFH/CFHR locus
yielded 9 different haplotypes with a predicted population
Figure 3. Graphs showing systemic complement activation levels stratified by rs3753396 and rs6685931 genotypes: rs6685931 introduced additional variation
on the main effect of rs3753396. The y-axes represent the ln-transformed complement C3d/C3 ratio as a measure of systemic complement activation. Hor-
izontal bars indicate the mean values for each genotype group. The complement-raising alleles for both single nucleotide polymorphisms are indicated in red.
Association analyses included the 2245 individuals from the discovery and the replication cohorts. A, Distribution of complement activation levels for each
genotype of rs3753396 in CFH. B, Distribution of complement activation levels for each genotype of rs6685931 in CFHR4. P values were calculated adjusting
the model for rs3753396. C, Distribution of complement activation levels over the genotype combinations of rs3753396 in CFH and rs6685931 in CFHR4.
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frequency higher than 1% (Table 7; Table S8, available at
www.aaojournal.org).
Association with systemic complement activation levels
revealed haplotypes with stronger effects on complement activation
compared with the single SNPs identified in the GWAS. Haplo-
types H1e2, H3, and H6 were associated with higher systemic
complement activation levels. Haplotype H3 carrying the
complement-raising allele of rs3753396 (G) had a stronger effect
on complement activation levels (P ¼ 2.53  1014; b ¼ 0.183;
SE, 0.024) compared with the complement-raising allele of
rs3753396 in the single variant analysis (b ¼ 0.141; SE, 0.015).
Haplotypes H1e2 and H6 both carried the complement-raising
allele for rs6685931 (C). Haplotype H6 showed a stronger effect
on complement activation levels (P ¼ 4.82  104; b ¼ 0.144; SE,
0.041) compared with the single variant analysis for rs6685931
(b ¼ 0.054; SE, 0.010; Table 7; Table S8, available at
www.aaojournal.org).
The Single Nucleotide Polymorphism rs6685931
in CFHR4 and Haplotype H1e2 Confer a Risk for
Age-Related Macular Degeneration
To identify genetic biomarkers that are relevant in the context of
disease, we explored whether the SNPs and haplotypes associated
with systemic complement activation levels also associate with
AMD. The SNP rs3753396 in CFH was not associated with AMD
(P ¼ 0.76). In contrast, the complement-raising allele of rs6685931
in CFHR4 (C) was associated with an increased risk for AMD
(P ¼ 5.89  1012; odds ratio ¼ 1.631; 95% confidence interval,
1.489e1.772; Table 9). These results are in concordance with the
largest GWAS on AMD reported to date (rs3753396, P ¼ 3 
103; rs6685931, P ¼ 1.02  10495; odds ratio >1).9
In agreement with the single variant analysis of CFH
rs3753396, the haplotype H3 that gave the highest risk for higher
systemic complement activation was not associated with AMD
(P ¼ 0.80). Haplotype H6 carries the CFHR4 rs6685931
complement-raising allele (C), but did not reach significance in the
association with AMD (P ¼ 0.14); however, the frequency of H6
was relatively low (3%). Haplotype H1e2, the most common
haplotype carrying the CFHR4 rs6685931 complement-raising
allele (C), showed a strong risk-conferring association with
AMD (P ¼ 1.38  1012; odds ratio ¼ 1.318; 95% confidence
interval, 1.223e1.420; Table 9; Fig 4).
Finally, we determined whether other AMD-associated variants
are associated with systemic complement activation levels. For this
purpose, we extracted the 52 AMD-associated variants reported in
the largest AMD study performed so far from the GWAS on
complement activation levels.9 However, no variants outside of the
CFH/CFHR locus were found to be associated with systemic
complement activation levels at the genome-wide significance
level, or at a significance level of P < 0.05/52 ¼ 0.001 (Table S10,
available at www.aaojournal.org). Interestingly, a risk score based
on the 52 AMD risk-conferring alleles was associated with higher
levels of complement activation (P ¼ 0.043; b ¼ 0.004; SE(b) ¼
0.002). A similar risk score including only the variants located in or
near complement genes was associated more strongly with higher
levels of complement activation (P ¼ 0.022; b ¼ 0.009; SE(b) ¼
0.004). This complement risk score included 3 nominally associated
variants: 2 common variants located in the CFH and the C2/CFB/
SKIV2L locidrs10922109 and rs116503776, respectivelydand a
rare variant located in the CFI gene, rs141853578 or p.Gly119Arg.
However, the effects of these genetic risk scores are smaller
Table 6. Model of Genetic and Nongenetic Variables Explaining
18.7% of the Variability in Systemic Complement Activation
b Standard Error (b) P Value
CFH rs3753396
AG 0.196 0.023 8.772  1017
GG 0.330 0.066 6.461  107
CFHR4 rs6685931
TC 0.070 0.024 0.003
CC 0.125 0.033 1.620  104
CFH rs800292
GA 0.011 0.023 0.639
AA 0.027 0.046 0.555
C2 rs9332739
GC 0.185 0.034 4.674  108
CC 0.168 0.213 0.431
Age (yrs) 0.004 0.001 0.005
Disease status (AMD) 0.035 0.020 0.089
BMI (kg/m2) 0.012 0.003 2  106
Triglycerides (mmol/l) 0.131 0.011 1.177  1033
AMD ¼ age-related macular degeneration; BMI ¼ body mass index.
R2 ¼ 0.193 (adjusted R2 ¼ 0.187). The model included the 1548 in-
dividuals from the discovery phase.
Table 7. Association of Haplotypes across the CFH/CFHR Locus with Systemic Complement Activation Levels
Haplotype
CFH rs3753396 and
CFHR4 rs6685931 Alleles Haplotype Frequency b Standard Error (b) P Value
H2 A-T 0.18 Reference Reference Reference
H1e2 A-C 0.36 0.062 0.019 1.148  103
H3 G-T 0.14 0.183 0.024 2.531  1014
H4 A-T 0.10 0.013 0.026 0.607
H5 A-T 0.04 0.058 0.038 0.128
H1e1 A-T 0.03 0.053 0.043 0.218
H6 A-C 0.03 0.144 0.041 4.823  104
H7 A-C 0.03 0.060 0.046 0.192
H8 A-T 0.03 0.007 0.048 0.890
Haplotype association analyses with age-related macular degeneration were performed for the 1548 individuals in the discovery cohort. Haplotypes are coded
as in Hageman et al.34 If 2 different subhaplotypes based on the extra allele in single nucleotide polymorphism rs6685931 were found, the Hageman
haplotypes were recoded as 1 or 2. Alleles associated with higher complement levels are underlined. The reference haplotype was set to the most
common haplotype not carrying any complement-raising allele for rs3753396 or rs6685931.
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compared with the single variant effects in the model for systemic
complement activation described in Table 6.
Discussion
We conducted a GWAS on systemic complement activation
levels, evaluating for an unbiased approach the genetic risk
factors involved in the activation of this essential component
of the immune system. We identified and replicated 2
common variants, rs3753396 and rs6685931, that lead to
higher systemic complement activation levels independently
of age, sex, AMD disease status, triglycerides, and BMI.
These 2 variants were included in a model for systemic
complement activation, which explained 18.7% of its
variability.
The SNP rs3753396 (c.2016A/G, p.Gln672Gln) is a
coding, synonymous variant located in exon 14 of the CFH
gene, and therefore this variant, or the linked causal vari-
ant(s), may regulate complement activation levels through
FH. Factor H is a key negative regulator of the AP and the
amplification loop of the complement cascade, which is
expressed constitutively in the liver and locally by other cell
types, such as retinal pigment epithelial and endothelial
cells.35e37 Evidence to support the theory that rs3753396
exerts an effect on complement activation through FH
comes from genetic studies on other diseases. The SNP
rs3753396 has been reported to be associated with atypical
hemolytic uremic syndrome, known to be caused by muta-
tions in CFH.38,39 Moreover, reduced susceptibility to
meningococcal disease also has been associated with
rs3753396. Meningococcal disease is caused by Neisseria
meningitides, which binds FH to avoid complement-
mediated killing.40 The SNP rs3753396 is in linkage
disequilibrium with rs1065489, also located in CFH
(c.2808G/T, p.Glu936Asp), which was proposed to be
the causal variant for meningococcal disease based on in
silico pathogenicity predictions.41
The SNP rs6685931 (c.59e4315T/C) is located in
intron 1 of the CFHR4 gene. Factor H related 4 (FHR-4) is a
glycoprotein that, in contrast to the attenuating effects of
FH, seems to promote complement activation. It binds the
complement fluid-phase C3b and forms an additional AP C3
convertase (FHR4-C3bBb), which is less susceptible to FH-
mediated decay.42 However, because rs6685931 is in high
linkage disequilibrium (r2 > 0.8) with several variants
located in the CFH gene, either FH or FHR-4 could be
responsible for the effects observed on complement
activation.
We analyzed the association of genetic variants with
systemic complement activation levels in a hypothesis-free
manner. The results indicate that with our study design,
the genetic variants with the largest effect on complement
activation levels are rs3753396 and rs668593, located at the
CFH/CFHR locus. Moreover, other previously associated
variants in CFH and C2/CFB could be replicated.18
Haplotype analysis at the CFH/CFHR locus revealed 2
haplotypes with stronger effects on complement activation
levels compared with the individual SNPs. These findings
suggest that additional variants at the CFH/CFHR locus
play a role in the activation of the complement system.
Indeed, several rare coding variants in the CFH gene have
been shown to lead to increased complement activity.10
Genetic variants in other genes that influence systemic
complement activation levels may be uncovered with
larger sample sizes that would allow for the detection of
rarer variants and smaller effects. A compelling rare
variant candidate that may merit further investigation is
CFI rs141853578 (p.Gly119Arg), which was found to be
nominally significant in our study. This variant has been
Figure 4. Graph showing complement activation levels stratified by
common haplotypes across the CFH/CFHR locus. The AMD risk haplo-
type H1e2 shows high complement activation levels, and the noneAMD-
associated H3e1 haplotype shows the highest. Horizontal bars indicate the
mean values for each haplotype carrier group. Haplotype carriers included
in the graph had a posterior probability higher than 0.75. The haplotype
group colors indicate the association with AMD: orange, protective; blue,
risk conferring; grey, not associated. Association analyses were carried out
for the 1548 patients genotyped with exome array.
Table 9. Association of Complement-Raising Single Nucleotide
Polymorphism and Haplotypes with Age-Related Macular
Degeneration: Single Nucleotide Polymorphism rs6685931 and
Haplotype H1e2 Confer a Risk for Age-Related Macular
Degeneration
Odds Ratio Confidence Interval P Value
SNP rs3753396 1.031 0.839e1.223 0.756
SNP rs6685931 1.631 1.489e1.772 5.889  1012
Haplotype H3 1.015 0.911e1.130 0.795
Haplotype H6 0.828 0.637e1.075 0.135
Haplotype H1e2 1.318 1.223e1.420 1.382  1012
SNP ¼ single nucleotide polymorphism.
Single variant and haplotype association analyses with age-related macular
degeneration were performed for the 1548 individuals from the discovery
cohort. Haplotype analyses were based on chi-squared tests that compared
the frequency of the analyzed haplotypes in patients versus controls.
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associated previously with lower factor I levels in plasma
and a lower ability to degrade C3d on the cell surface and
C3b in the fluid phase.43
In this study, AMD was associated with systemic com-
plement activation, which is in agreement with previous
reports.15e18,20 In our analysis, rs6685931 in CFHR4 was
associated with both systemic complement activation and
AMD. Haplotype analyses were in line with these results;
we observed that the complement-raising allele of SNP
rs6685931 (C) was located mainly on the H1e2 haplotype,
which associated with a higher risk for AMD development.
Thus, this SNP and its linked haplotype could serve as a
robust biomarker for complement activation in the context
of AMD and could be used to identify AMD patients who
would benefit most from complement-inhibiting therapies.
We noted that the rare haplotype H6 (with a frequency of
3%), also containing rs6685931, had a larger effect on
complement activation levels compared with the single
variant rs6685931. However, haplotype H6 was not asso-
ciated significantly with AMD, probably because of statis-
tical power limitations. Studies with larger cohort sizes may
clarify the role of the H6 haplotype in AMD and may
identify other rare haplotypes that associate with AMD and
have larger effects on complement activation levels.
Strikingly, the genetic variant that was associated most
strongly with systemic complement activation, rs3753396 in
CFH, and its main haplotype (H3) did not associate with
AMD. However, the SNP rs3753396 and haplotype H3
have been described to confer risk for atypical hemolytic
uremic syndrome development. Atypical hemolytic uremic
syndrome is a complement system-related disease that leads
to systemic thrombotic microangiopathy and renal endo-
thelial injury.39,44 This finding suggests that the effect of the
haplotypes may be different systemically compared with the
AMD disease site, possibly through a tissue-specific effect
of the genetic variants. Consequently, systemic complement
activation may not always reflect complement activation in
the disease tissue, and therefore, it may not be the most
appropriate measure for AMD studies. Genetic biomarkers
such as SNP rs6685931 and haplotype H1e2 are robust
markers that, together with the C3d-to-C3 ratio, could serve
as biomarkers for complement activity studies in AMD.
This is supported by a recent study demonstrating that
complement activation levels in aqueous humor are higher
than in plasma samples of AMD patients.45 As a
consequence, the effect of rs6685931 and H1e2 on local
complement activation may be even larger than the effect
seen on systemic levels.
Our results also could further the understanding of other
complement-related diseases, as well as be used in the
context of personalized medicine involving FH supple-
mentation therapy and other complement-targeting
therapies.46e48 Besides N. meningitidis, a number of bac-
teria, fungi, parasites, and viruses bind FH to avoid elimi-
nation by the alternative pathway of the complement
system.49 Also, some cancer cells express FH to avoid being
targeted by the immune system.50e52 Other FH-related
diseases for which our results may be of interest include
hemolytic uremic syndrome, atypical hemolytic uremic
syndrome, encephalomyelitis, atherosclerosis, insulin
resistance, immunoglobulin A nephropathy, Alzheimer’s
disease, cisplatin nephropathy, as well as severe dengue, for
which variants in the CFH gene have been shown to be
protective.53
In conclusion, we identified 2 common variants located
at the CFH/CFHR locus, rs3753396 and rs668593, which
strongly influence systemic complement activation levels.
Moreover, our haplotype studies suggest that other genetic
variants in the CFH/CFHR locus influence systemic com-
plement activation. Genetic and nongenetic factors identi-
fied in this and other studies explain up to 18.7% of the
variability in systemic complement activation levels. The
common variant rs6685931 in CFHR4, and its associated
haplotype H1e2, could be used, together with other envi-
ronmental factors as well as rare genetic variants, to select
AMD patients who would benefit from complement-
inhibiting therapies.
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